David Kabakoff, Ph.D. has served as a member of our board of directors since September 2017. Since 2012, Dr. Kabakoff has served as a partner at HealthQuest Capital. Since 2007, Dr. Kabakoff has also served as an executive partner at Sofinnova Ventures. Dr. Kabakoff currently serves as chairman of the board of directors of NextCure, Inc., a publicly traded biopharmaceutical company. Dr. Kabakoff also serves on the board of directors of several private companies, including Antiva Biosciences, Inc., a biopharmaceutical company, Dauntless Pharmaceuticals, a biopharmaceutical company, Rarecyte, Inc., a life science tools company, Rainier Therapeutics, Inc., a biopharmaceutical company and Neurana Pharmaceuticals, Inc., a biopharmaceutical company. From 2006 until October 2014, Dr. Kabakoff served as a director of InterMune Inc., a publicly traded biopharmaceutical company. In 2001 Dr. Kabakoff co-founded Salmedix, Inc., a developer of cancer drug treatments, served as its Chairman and Chief Executive Officer and led its acquisition in June 2005 by Cephalon, Inc., a biopharmaceutical company. From 1996 to 2000, Dr. Kabakoff held the positions of Executive Vice President of Dura Pharmaceuticals, Inc. and President and Chief Executive Officer of Spiros, both pharmaceutical companies. From 1989 to 1996, Dr. Kabakoff was employed as Chief Executive Officer of Corvas International, Inc., a developer of biotherapeutics, and from 1983 to 1989 held senior executive positions with Hybritech, a biotechnology company. Dr. Kabakoff holds a B.A. degree in Chemistry from Case Western Reserve University and a Ph.D. from Yale University.
What is David S. Kabakoff's net worth?
The estimated net worth of David S. Kabakoff is at least $6.33 million as of June 22nd, 2020. Mr. Kabakoff owns 212,178 shares of Castle Biosciences stock worth more than $6,325,026 as of November 22nd. This net worth evaluation does not reflect any other investments that Mr. Kabakoff may own. Learn More about David S. Kabakoff's net worth.
How do I contact David S. Kabakoff?
Has David S. Kabakoff been buying or selling shares of Castle Biosciences?
David S. Kabakoff has not been actively trading shares of Castle Biosciences during the last quarter. Most recently, David S. Kabakoff sold 30,000 shares of the business's stock in a transaction on Thursday, June 17th. The shares were sold at an average price of $75.07, for a transaction totalling $2,252,100.00. Learn More on David S. Kabakoff's trading history.
Who are Castle Biosciences' active insiders?
Are insiders buying or selling shares of Castle Biosciences?
During the last year, insiders at the sold shares 44 times. They sold a total of 233,784 shares worth more than $5,324,298.53. The most recent insider tranaction occured on November, 15th when CFO Frank Stokes sold 6,923 shares worth more than $207,205.39. Insiders at Castle Biosciences own 7.2% of the company.
Learn More about insider trades at Castle Biosciences. Information on this page was last updated on 11/15/2024.
